Thomas Sbarrato

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape

A. Modelska, Ernest Turro, Robert B. Russell et al. · Cell Death and Disease · 2015 · 172 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3

Amandine Bastide, Diego Peretti, John R. P. Knight et al. · Current Biology · 2017 · 86 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

François Ghiringhelli, Frédéric Bibeau, Laurent Greillier et al. · EBioMedicine · 2023 · 86 citations · Full text

Life Sciences, Oncology, Pathology +17

Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4

Joy Ogbechi, Belinda S. Hall, Thomas Sbarrato et al. · Cell Death and Disease · 2018 · 84 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17